Singapore’s state investment firm Temasek Holdings has led a RMB400 million(US$59 million) series B round in Hangzhou Just Bioteherapeutics Ltd., a Chinese antibody and recombinant protein bio-therapeutics developer.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?